ALX Oncology reports Q3 net loss $0.58/share; CFO Garcia resigns, Pinto interim

ALX ONCOLOGY HOLDINGS INC

2024-Q3 EPS reported -$2.05

GAAP net loss $30.7M ($0.58 per share) vs $51.0M ($1.24) in Q3 2023; non-GAAP net loss $23.7M.
R&D expenses fell to $26.5M from $45.8M YoY; cash $162.6M sufficient into Q1 2026.
Evorpacept ASPEN-06 Phase 2 gastric/GEJ cancer showed 40.3% ORR vs 26.6% control; median duration 15.7 months.
CFO Peter Garcia resigns effective Nov 8; Shelly Pinto (SVP Finance, CAO) appointed interim CFO.
Upcoming milestones: Phase 3 registrational trial for evorpacept in gastric/GEJ mid-2025; SABCS breast cancer Dec 12.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Peter Garcia

Chief Financial Officer

ALXO · ALX ONCOLOGY HOLDINGS INC

Effective: 2024-11-08
Successor: Shelly Pinto
Filed: November 7, 2024, 6:59 PM ET

On November 5, 2024, Peter Garcia, Chief Financial Officer of the Company informed the Company of his resignation from his position effective November 8, 2024, due to personal reasons.

Appointed (interim)

Shelly Pinto

Interim Chief Financial Officer

ALXO · ALX ONCOLOGY HOLDINGS INC

Effective: 2024-11-08
Filed: November 7, 2024, 6:59 PM ET

On November 7, 2024, the Board of Directors (the “Board”) of the Company appointed Shelly Pinto, the Company’s Senior Vice President, Finance and Chief Accounting Officer, as the Company’s interim Chief Financial Officer, effective upon Mr. Garcia’s resignation.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter Garcia resigned as Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On November 5, 2024, Peter Garcia, Chief Financial Officer of the Company informed the Company of his resignation from his position effective November 8, 2024, due to personal reasons.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Shelly Pinto was appointed as Interim Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

On November 7, 2024, the Board of Directors (the “Board”) of the Company appointed Shelly Pinto, the Company’s Senior Vice President, Finance and Chief Accounting Officer, as the Company’s interim Chief Financial Officer, effective upon Mr. Garcia’s resignation.

View on SEC.gov

ALX ONCOLOGY HOLDINGS INC filing history →

Source: SEC EDGAR

accession 0000950170-24-123252

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.